Galmed Pharmaceuticals Stock Probability of Future Stock Price Finishing Under 2.61
| GLMD Stock | USD 2.75 0.05 1.79% |
Galmed |
Galmed Pharmaceuticals Target Price Odds to finish below 2.61
The tendency of Galmed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 2.61 or more in 90 days |
| 2.75 | 90 days | 2.61 | about 20.07 |
Based on a normal probability distribution, the odds of Galmed Pharmaceuticals to drop to $ 2.61 or more in 90 days from now is about 20.07 (This Galmed Pharmaceuticals probability density function shows the probability of Galmed Stock to fall within a particular range of prices over 90 days) . Probability of Galmed Pharmaceuticals price to stay between $ 2.61 and its current price of $2.75 at the end of the 90-day period is about 1.93 .
Given the investment horizon of 90 days Galmed Pharmaceuticals has a beta of -0.54. This usually indicates as returns on the benchmark increase, returns on holding Galmed Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Galmed Pharmaceuticals is likely to outperform the market. In addition to that Galmed Pharmaceuticals has an alpha of 2.4527, implying that it can generate a 2.45 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Galmed Pharmaceuticals Price Density |
| Price |
Predictive Modules for Galmed Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Galmed Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Galmed Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Galmed Pharmaceuticals is not an exception. The market had few large corrections towards the Galmed Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Galmed Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Galmed Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.45 | |
β | Beta against Dow Jones | -0.54 | |
σ | Overall volatility | 2.09 | |
Ir | Information ratio | 0.06 |
Galmed Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Galmed Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Galmed Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Galmed Pharmaceuticals is way too risky over 90 days horizon | |
| Galmed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Galmed Pharmaceuticals Stock Crosses Below 200 Day Moving Average Time to Sell |
Galmed Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Galmed Stock often depends not only on the future outlook of the current and potential Galmed Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Galmed Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 230.8 K | |
| Cash And Short Term Investments | 12.6 M |
Galmed Pharmaceuticals Technical Analysis
Galmed Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Galmed Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Galmed Pharmaceuticals. In general, you should focus on analyzing Galmed Stock price patterns and their correlations with different microeconomic environments and drivers.
Galmed Pharmaceuticals Predictive Forecast Models
Galmed Pharmaceuticals' time-series forecasting models is one of many Galmed Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Galmed Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Galmed Pharmaceuticals
Checking the ongoing alerts about Galmed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Galmed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Galmed Pharmaceuticals is way too risky over 90 days horizon | |
| Galmed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Galmed Pharmaceuticals Stock Crosses Below 200 Day Moving Average Time to Sell |
Check out Galmed Pharmaceuticals Backtesting, Galmed Pharmaceuticals Valuation, Galmed Pharmaceuticals Correlation, Galmed Pharmaceuticals Hype Analysis, Galmed Pharmaceuticals Volatility, Galmed Pharmaceuticals History as well as Galmed Pharmaceuticals Performance. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.